also known as advantagene. inc., we are a massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our gene mediated cytotoxic (gmci™) platform and our rqnestin34.5 platform. gmci™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
Company profile
Ticker
CADL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Candel Therapeutics Securities Corporation ...
IRS number
522214851
CADL stock data
Latest filings (excl ownership)
8-K
Candel Therapeutics Announces Upcoming Presentations
25 Apr 24
10-K/A
2023 FY
Annual report (amended)
25 Apr 24
8-K
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
11 Apr 24
8-K
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
9 Apr 24
8-K
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
4 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
28 Mar 24
8-K
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
6 Mar 24
424B5
Prospectus supplement for primary offering
13 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 43.25 mm | 43.25 mm | 43.25 mm | 43.25 mm | 43.25 mm | 43.25 mm |
Cash burn (monthly) | 2.97 mm | 2.85 mm | 2.95 mm | 3.01 mm | 2.94 mm | 2.81 mm |
Cash used (since last report) | 20.43 mm | 19.61 mm | 20.32 mm | 20.74 mm | 20.20 mm | 19.32 mm |
Cash remaining | 22.82 mm | 23.64 mm | 22.93 mm | 22.51 mm | 23.05 mm | 23.93 mm |
Runway (months of cash) | 7.7 | 8.3 | 7.8 | 7.5 | 7.9 | 8.5 |
Institutional ownership, Q2 2023
20.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 2 |
Closed positions | 6 |
Increased positions | 2 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 5.60 bn |
Total shares | 6.14 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Northpond Ventures | 1.94 mm | $2.44 bn |
Northpond Ventures | 1.69 mm | $0.00 |
BEN Franklin Resources | 1.13 mm | $1.42 bn |
FMR | 452.56 k | $570.22 mm |
Vanguard | 405.76 k | $511.25 mm |
Bridgeway Capital Management | 132.60 k | $167.07 mm |
Geode Capital Management | 131.20 k | $165.32 mm |
C Citigroup | 118.61 k | $149.45 mm |
BLK Blackrock | 51.82 k | $65.30 mm |
STT State Street | 27.60 k | $34.78 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Nov 23 | Paul Peter Tak | Common Stock | Payment of exercise | Dispose F | No | No | 0.9 | 43,443 | 39.10 k | 373,556 |
28 Nov 23 | Garrett Nichols | Common Stock | Payment of exercise | Dispose F | No | No | 0.9 | 12,175 | 10.96 k | 135,126 |
28 Nov 23 | Francesca Barone | Common Stock | Payment of exercise | Dispose F | No | No | 0.9 | 19,748 | 17.77 k | 186,657 |
28 Nov 23 | Jason Amello | Common Stock | Payment of exercise | Dispose F | No | No | 0.9 | 20,153 | 18.14 k | 202,009 |
News
How Is The Market Feeling About Candel Therapeutics?
19 Apr 24
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Apr 24
What's Going On With Candel Therapeutics Stock?
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation For CAN-2409 For The Treatment Of Pancreatic Cancer
11 Apr 24
Press releases
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology
16 Apr 24
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology
15 Apr 24
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
9 Apr 24
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
28 Mar 24
Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors
15 Mar 24